{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:14:04Z","timestamp":1791231244270,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.ygyno.2011.12.415","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T23:49:01Z","timestamp":1326930541000},"page":"347-353","source":"Crossref","is-referenced-by-count":120,"title":["Hereditary ovarian cancer: Beyond the usual suspects"],"prefix":"10.1016","volume":"124","author":[{"given":"Kathryn P.","family":"Pennington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.12.415_bb0005","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0015","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.955","article-title":"Mutations in BRIP1 confer high risk of ovarian cancer","volume":"43","author":"Rafnar","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0020","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMra0809889","article-title":"Susceptibility pathways in Fanconi's anemia and breast cancer","volume":"362","author":"D'Andrea","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA1 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0035","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0045","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ng1096-188","article-title":"The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%","volume":"14","author":"Oddoux","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0050","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ng1095-198","article-title":"The carrier frequency of the BRCA1 185delAG mutation is approximately 1percent in Ashkenazi Jewish individuals","volume":"11","author":"Struewing","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0055","first-page":"1059","article-title":"Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families","volume":"60","author":"Levy-Lahad","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0060","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/302853","article-title":"BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer","volume":"66","author":"Moslehi","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0065","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0090-8258(03)00152-5","article-title":"Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel","volume":"89","author":"Hirsh-Yechezkel","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0070","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0075","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0080","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0085","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0090","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1158\/1078-0432.CCR-1029-3","article-title":"Pathology of ovarian cancers in BRCA1 and BRCA2 carriers","volume":"10","author":"Lakhani","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0095","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0100","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.pgp.0000101083.35393.cd","article-title":"Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry","volume":"23","author":"Werness","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","article-title":"Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer","volume":"26","author":"Chetrit","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0115","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0120","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdq628","article-title":"Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients","volume":"22","author":"Vencken","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0130","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1038\/sj.onc.1205685","article-title":"Significant contribution of large BRCA1 gene rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments","volume":"21","author":"Gad","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0135","first-page":"455","article-title":"Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions","volume":"59","author":"Puget","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0140","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.295.12.1379","article-title":"Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer","volume":"295","author":"Walsh","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0145","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1086\/303076","article-title":"Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing","volume":"67","author":"Unger","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0150","first-page":"1449","article-title":"Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method","volume":"63","author":"Hogervorst","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.gastro.2005.05.011","article-title":"Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset","volume":"129","author":"Hampel","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0160","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2009.07.039","article-title":"Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome","volume":"137","author":"Stoffel","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/hmg\/6.1.105","article-title":"Cancer risk associated with germline DNA mismatch repair gene mutations","volume":"6","author":"Dunlop","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0170","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/gyno.2001.6279","article-title":"The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer","volume":"82","author":"Watson","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10897-010-9325-x","article-title":"Genetic counseling considerations in the evaluation of families for Lynch syndrome\u2014a review","volume":"20","author":"Weissman","year":"2011","journal-title":"J Genet Couns"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0180","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/gcc.20678","article-title":"Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome","volume":"48","author":"Niessen","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.mrfmmm.2009.01.013","article-title":"Fanconi anemia and its diagnosis","volume":"668","author":"Auerbach","year":"2009","journal-title":"Mutat Res"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0190","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood-2005-10-4240","article-title":"Molecular pathogenesis of Fanconi anemia: recent progress","volume":"107","author":"Taniguchi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0195","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mrfmmm.2008.11.004","article-title":"The genetic and molecular basis of Fanconi anemia","volume":"668","author":"de Winter","year":"2009","journal-title":"Mutat Res"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0200","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ng.750","article-title":"Mutations of the SLX4 gene in Fanconi anemia","volume":"43","author":"Kim","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0205","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/ng.751","article-title":"SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype","volume":"43","author":"Stoepker","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0210","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.1073834","article-title":"Biallelic inactivation of BRCA2 in Fanconi anemia","volume":"297","author":"Howlett","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0215","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0220","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0225","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0165-4608(90)90004-T","article-title":"Cancer predisposition of ataxia\u2013telangiectasia heterozygotes","volume":"46","author":"Swift","year":"1990","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0230","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ng1837","article-title":"ATM mutations that cause ataxia\u2013telangiectasia are breast cancer susceptibility alleles","volume":"38","author":"Renwick","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0235","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1158\/1055-9965.EPI-07-0116","article-title":"Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11\/Rad50\/Nbs1 complex","volume":"16","author":"Hsu","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0240","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/gcc.1223","article-title":"Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast\/ovarian families negative for BRCA1 and BRCA2 alterations","volume":"33","author":"Ghimenti","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0245","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-10-3958","article-title":"Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer","volume":"71","author":"Casadei","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0250","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1086\/421251","article-title":"CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies","volume":"74","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0255","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/ng1902","article-title":"Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles","volume":"38","author":"Seal","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0260","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ng1959","article-title":"PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene","volume":"39","author":"Rahman","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0265","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2350-11-20","article-title":"A novel germline PALB2 deletion in breast and ovarian cancer patients","volume":"11","author":"Dansonka-Mieszkowska","year":"2010","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0270","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng.570","article-title":"Mutation of the RAD51C gene in a Fanconi anemia-like disorder","volume":"42","author":"Vaz","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0275","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/ng.666","article-title":"Common variants at 19p13 are associated with susceptibility to ovarian cancer","volume":"42","author":"Bolton","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0280","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/ng.668","article-title":"A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24","volume":"42","author":"Goode","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0285","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.424","article-title":"A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2","volume":"41","author":"Song","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0290","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMp0806284","article-title":"Common genetic variation and human traits","volume":"360","author":"Goldstein","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0295","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cell.2010.03.032","article-title":"Genetic heterogeneity in human disease","volume":"141","author":"McClellan","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0300","series-title":"Trait\u00e9 des Tumeurs","author":"Broca","year":"1866"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0305","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0140-6736(02)11023-3","article-title":"Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study","volume":"360","author":"Bergfeldt","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0310","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/jnci\/dji281","article-title":"Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families","volume":"97","author":"Kauff","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0315","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrg2841","article-title":"Advances in understanding cancer genomes through second-generation sequencing","volume":"11","author":"Meyerson","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0320","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2011.12.415_bb0325","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ng1196-253","article-title":"A polymorphic stop codon in BRCA2","volume":"14","author":"Mazoyer","year":"1996","journal-title":"Nat Genet"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811013886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811013886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T01:25:46Z","timestamp":1543281946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811013886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0090825811013886"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.12.415","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}